- Home
- HTH vs AUPH Comparison
HTH vs AUPH Comparison
Compare HTH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | AUPH |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HTH | AUPH |
|---|---|---|
| Price | $38.49 | $16.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $17.25 |
| AVG Volume (30 Days) | 197.6K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | 51.72 | ★ 5075.00 |
| EPS | ★ 1.27 | 0.53 |
| Revenue | $152,188,000.00 | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $3.22 | $15.74 |
| P/E Ratio | ★ $30.37 | $31.08 |
| Revenue Growth | 15.52 | ★ 20.38 |
| 52 Week Low | $30.78 | $10.34 |
| 52 Week High | $40.41 | $19.25 |
Technical Indicators
Market Signals| Indicator | HTH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 54.99 |
| Support Level | $38.34 | $14.61 |
| Resistance Level | $40.03 | $16.46 |
| Average True Range (ATR) | 0.57 | 0.48 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 28.04 | 50.68 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.